Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889862 | 0.86 | MAPT (0.61) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL69159 | 0.84 | ALDH1A1 (0.58) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL4908303 | 0.83 | BCAT2 (0.53) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5553175 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL29228925 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29161457 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL31622301 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL3375243 | 0.81 | MAPT (0.55) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| Malonic Acid SCHEMBL2887012 | 0.80 | MAPT (0.50) | ALDH1A1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL3621051 | 0.78 | DHODH (0.51) | ALDH1A1MAPTMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105593232-B | Benzoxazoloxazinone compounds as coagulation factor Xa inhibitors | 华北制药集团新药研究开发有限责任公司 | 2018-06-26 | — | — | CN | disclosed |
| EP-3181569-A1 | BENZOBIS(THIADIAZOLE) DERIVATIVE, INK CONTAINING SAME, AND ORGANIC ELECTRONIC DEVICE USING SAME | UBE Industries, Ltd. (JP) | 2017-06-21 | — | — | EP | disclosed |
| CN-105593232-A | Benzoxazoloxazinone compounds as coagulation factor Xa inhibitors | NORTH CHINA PHARMACEUTICAL NEW DRUG R & D CO LTD | 2016-05-18 | — | — | CN | disclosed |
| WO-2012156948-A1 | ORGANIC SEMICONDUCTOR MATERIAL | E.T.C. S.R.L. (IT) | 2012-11-22 | — | — | WO | disclosed |
| EP-1515972-B1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-05-13 | — | — | EP | disclosed |
| EP-1515972-B1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-05-13 | — | — | EP | disclosed |
| US-7135475-B2 | Antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1515972-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20040014766-A1 | Amide substituted xanthine derivatives | HOFFMANN-LA ROCHE INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003106459-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014766-A1 | Amide substituted xanthine derivatives | GYS2, GLS2, PYGL | ALDH1A1 297/4885MAPT 3897/4885MAPK1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.